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Abstract: BRAF exon 15 mutations are the most common molecular alterations found in papillary 
thyroid carcinoma (PTC). To date, there is no information regarding BRAF alterations in the thyroid 
parenchyma surrounding the tumor. To explore the early events associated with the development 
of PTC, we used massively parallel sequencing to investigate BRAF exon 15 in 30 PTCs and in 100 
samples from the thyroid parenchyma surrounding the tumor. BRAF p.V600E was identified in 
19/30 PTCs (63.3%). BRAF p.V600E mutations were identified in the tissue adjacent the PTC only in 
samples containing psammoma bodies. The other samples were either BRAF wild type (WT) or 
carried BRAF non p.V600E mutations. Specifically, BRAF p.G593D, -p.A598T, -p.V600M, -p.R603Q, 
-p.S607F, and -p.S607P were identified in 4 of 36 (11.1%) samples with follicular cell atypia, in 2 of 
16 (12.5%) with follicular cell hyperplasia, and in 1 of 33 (3.0%) histologically normal samples—only 
in tissue surrounding BRAF p.V600E mutated PTCs. These mutations are predicted to affect protein 
function in silico but, in vitro, have kinase activity and BRAF phosphorylation levels similar to BRAF 
WT. No BRAF exon 15 mutations were identified in samples adjacent to PTCs that were BRAF WT. 
A mutagenic process affecting BRAF exon 15 occurs in a subset of thyroid glands that develop BRAF 
p.V600E mutated PTCs.  
Keywords: papillary thyroid carcinoma; BRAF exon 15 mutations; BRAF p.V600E; tumor 
development; follicular cell atypia; follicular cell hyperplasia; psammoma bodies; massively parallel 
sequencing 
 
1. Introduction 
Papillary thyroid carcinoma (PTC) is the most common malignancy of the endocrine system [1], 
and its incidence has been increasing in the recent past, mostly due to the early detection of small 
asymptomatic tumors [1–3]. The molecular signature of PTC has been extensively investigated, and 
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a remarkable correlation between molecular alterations and PTC histologic phenotypes (i.e., PTC 
histotype variants) has become apparent [2,4]. The work of the Cancer Genome Atlas classification of 
PTC [4] has identified two molecular signatures: (i) BRAF p.V600E-like typical of classic/conventional 
PTC and (ii) RAS-like typical of the encapsulated follicular variant PTC, a tumor type with features 
that overlaps with other follicular patterned tumors, such as follicular thyroid adenoma and 
carcinoma [2,4,5]. BRAF exon 15 mutations are present in 40% to 80% of PTC, and the vast majority 
of them—i.e., greater than 95%—consist in a point mutation that involves nucleotide 1799 (thymine 
to adenine trans-version, c.1799T>A). The resulting valine to glutamate substitution at residue 600 
(BRAF p.V600E) mimics BRAF phosphorylation, causing constitutive activation of the protein [2]. 
Other far less common BRAF alterations include nucleotide changes associated with follicular 
patterned tumors (follicular adenoma, follicular carcinoma, and encapsulated follicular variant 
papillary carcinoma) and rearrangements associated with radiation-induced PTCs [2]. 
BRAF p.V600E mutation, like other single-nucleotide changes in BRAF or other genes relevant 
for thyroid tumorigenesis (e.g., H-, K-, and N-RAS), are supposed to result from exposure to chemical 
carcinogens, although very little is known about the process that leads to the occurrence of these 
simple genetic alterations [2]. In spite of the very high specificity of BRAF p.V600E for PTC [2], the 
BRAF exon 15 status of thyroid tissue surrounding the tumor is unknown.  
To test the mutagenic process that leads to BRAF p.V600E mutated PTCs, we used massively 
parallel sequencing to evaluate the BRAF exon 15 status in 100 thyroid tissue samples adjacent to 30 
PTCs, with the aim of better understanding whether potential precursor lesions are associated with 
the development of PTC. 
2. Results 
2.1. Clinicopathologic Features of Tumors and Histologic Features of Adjacent Thyroid Tissue 
Table S1 is a list of all samples analyzed. The clinicopathologic characteristics of the 30 PTCs are 
summarized in Table 1. Most tumors were classic papillary carcinomas (Figure 1a). One case was 
classified as infiltrative follicular variant PTC, a type of PTC that is known to have a BRAF p.V600E-
like profile [2]. Two cases were classified as encapsulated follicular variant papillary carcinoma, a 
type of PTC known to have an RAS-like molecular profile [2,4,6,7], and both had invasion of the tumor 
capsule. Thyroid tissue from the parenchyma surrounding the PTC was selected from areas that were 
histologically normal (34 samples), that had follicular cell atypia (38 samples) or follicular cell 
hyperplasia (16 samples), that contained psammoma bodies in the absence of tumor cells as seen 
under the microscope (6 samples), or from follicular adenomas (one of which was oncocytic) that 
coexisted with a PTC in four of the thirty thyroidectomy specimens (Table 1 and Figure 2; we 
analyzed two samples from the oncocytic follicular adenoma, two samples from one follicular 
adenoma, and one sample each from the remaining two follicular adenomas). Psammoma bodies are 
round calcific tridimensional structures with distinctive concentric laminations found in the thyroid 
stroma or in the vicinity of lymphatic vessels (Figure 1b) that are considered a histologic marker for 
PTC [6]. The areas of follicular cell atypia (Figure 1c) were defined by the presence of unusual 
features, including follicular cell crowding and minor alterations of the nuclear morphology, such as 
mild nuclear clearing, mild enlargement, and contour irregularities, similar to what is described in 
multifocal fibrosing (sclerosing) thyroiditis [7]. The areas of follicular cell hyperplasia (Figure 1d) 
consisted of millimetric foci of increased cellular density with microfollicles and enlarged follicular 
cells similar to those observed in the hyperplastic nodules of multinodular goiter [6]. 
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Table 1. Clinicopathologic characteristics of papillary thyroid carcinomas (n = 30). 
Clinicopathologic Features Number (%) 
Age (years) 47.6 ± 13.6a 
Female sex 20 (66.7%) 
Papillary carcinoma  
Classic 24 (80.0%) 
Tall cell variant 3 (10.0%) 
Follicular variant-infiltrative  1 (3.3%) 
Follicular variant-encapsulated with capsular invasion 2 (6.7%) 
Tumor size (cm) 1.5 ± 1a 
BRAF p.V600E mutation 20 (66.7%) 
Lymph node metastasis 12 (40.0%) 
ATA (2015) recurrence risk groups  
Low risk 12 (40.0%) 
Intermediate risk  18 (60.0%) 
AJCC stage (8th ed.)  
I 29 (96.7%) 
II 1 (3.3%) 
Other thyroid pathology  
Follicular adenoma 3 (10%) 
Follicular adenoma, oncocytic 1 (3.3%) 
Chronic thyroiditis 4 (13.3%) 
Graves-Basedow disease 1 (3.3%) 
amean + standard deviation. 
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Figure 1. Histologic appearance of the samples analyzed (a, b, c, and d). (a) Papillary carcinoma BRAF p.V600E mutated (×100). (b) Psammoma body (arrow) protruding 
into a dilated lymphatic space (×100); the inset shows the psammoma body at higher magnification and in the plane of focus (×400). BRAF p.V600E is identified after 
sequencing of DNA extracted from the area containing the psammoma body. (c) Focus of follicular cell atypia (×200) (arrows, inset at higher magnification, ×400). BRAF 
p.V600M is identified after the sequencing of DNA extracted from the area with follicular cell atypia. (d) Focus of follicular cell hyperplasia with oncocytic change (×200) 
(arrows, inset at higher magnification, ×400). BRAF p. S607P is identified after the sequencing of DNA extracted from the area with follicular cell hyperplasia. 
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Figure 2. BRAF exon 15 status in thyroid samples. Bars represent the number of samples that are 
BRAF p.V600E, BRAF non p.V600E mutated, and BRAF wild type (WT). Percentages are in 
parenthesis. Two separate samples were analyzed from one follicular adenoma for a total of four 
samples from three follicular adenomas. Two separate samples were analyzed from one oncocytic 
follicular adenoma. PTC: papillary thyroid carcinoma; PTC-CL: classic PTC; PTC-TC: PTC, tall cell 
variant; PTC-FV-INF: PTC follicular variant—infiltrative; PTC-FV-ENCAPS-CAPSINV: PTC 
follicular variant—encapsulated, with capsular invasion; PsB: psammoma bodies; FA: follicular 
adenoma; FA-ONC: follicular adenoma, oncocytic; ATY: thyroid tissue with follicular cell atypia; 
HYP: thyroid tissue with follicular cell hyperplasia; and NORM: histologically normal thyroid tissue. 
2.2. BRAF Exon 15 Mutations in Papillary Carcinoma 
The results are summarized in Table S1, Table 2, and Figure 2. One representative case with a 
BRAF p.V600E mutation is illustrated in Figure 1a. Overall, the BRAF p.V600E mutation was 
identified in 19/30 cases (63.3%), including 15/24 classic PTCs (62.5%), all tall cell variant PTCs (3/3, 
100%), and the only infiltrative follicular variant PTC (1/1, 100%). The only PTC with a BRAF non 
p.V600E mutation (Case 21, Table S1) was BRAF p.V600A mutated. BRAF p.V600A is a RAS-like BRAF 
exon 15 mutation according to the Cancer Genome Atlas classification of papillary thyroid carcinoma 
[4] and is compatible with the diagnosis of encapsulated follicular variant papillary carcinoma. 
2.3. BRAF Exon 15 Mutations in Thyroid Tissue Adjacent to Papillary Carcinoma 
One hundred samples from thyroid tissue surrounding the PTCs were analyzed. The results are 
summarized in Table S1, Table 2, Table 3, Table 4, Figure 2, and Figure 3; representative cases are 
illustrated in Figure 1b, Figure 1c, Figure 1d. In these cases, BRAF p.V600E was identified in three of 
six samples containing psammoma bodies (without viable tumor cells) (Table 2, Figure 1b, and Figure 
2); in all three cases, BRAF p.V600E was also present in the PTC (Table S1). The three samples with 
psammoma bodies without BRAF mutations were obtained from thyroid tissue surrounding PTCs 
that were BRAF WT (Table S1).  
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Table 2. BRAF Exon 15 mutations in PTC (n = 30) and in adjacent thyroid tissue (n = 100). 
Samples Analyzed  
(n = 130) 
BRAF p.V600E BRAF non 
p.V600E 
BRAF WT NA Total 
(Samples) 
Papillary carcinoma, all 
cases (n = 30) 
19/130 (14.6%) 1/130 (0.8%) 10/130 (7.7%) - 30/130 (23.1%) 
Papillary carcinoma Classic  
(n = 24) 15/130 (11.5%) - 9/130 (6.9%) - 24/130 (18.5%) 
Papillary carcinoma Tall cell 
variant (n = 3) 3/130 (2.3%) - - - 3/130 (2.3%) 
Papillary carcinoma Follicular 
variant—infiltrative (n = 1) 1/130 (0.8%) - - - 1/130 (0.8%) 
Papillary carcinoma Follicular 
variant—encapsulated with 
capsular invasion (n = 2) 
- 1/130 (0.8%)a 1/130 (0.8%) - 2/130 (1.5%) 
Thyroid tissue adjacent the 
papillary carcinoma 
(n = 100) 
     
Psammoma Body (n = 6) 3/130 (2.3%) - 3/130 (2.3%) - 6/130 (4.6%) 
Follicular Adenoma (n = 4) - 1/130 (0.8%) 3/130 (2.3%) - 4/130 (3.1%) 
Oncocytic Follicular Adenoma 
(n = 2) - 1/130 (0.8%) 1/130 (0.8%) - 2/130 (%) 
Follicular cell atypia 
(n = 38) - 4/130 (3.1%) 32/130 (24.6%) 2/130 (1.5%) 38/130 (29.2%) 
Follicular cell hyperplasia 
(n = 16) - 2/130 (1.5%) 14/130 (10.8) - 16/130 (12.3%) 
Histologically normal 
(n = 34) - 1/130 (0.8%) 32/130 (24.6%) 1/130 (0.8%) 34/130 (26.2%) 
Total (Mutation status) 22/130 (16.9%) 10/130 (7.7%) 95/130 (73.1%) 3/130 (2.3%) 130/130 (100%) 
aThe single PTC with a BRAF non p.V600E mutation was p.V600A mutated (Case 21, Table S1). 
Thus, there was a perfect correspondence between BRAF exon 15 status of the PTC and of the 
psammoma bodies surrounding the tumor. The other samples from thyroid tissue adjacent to the 
PTC were either BRAF exon 15 WT or carried BRAF non p.V600E mutations. The overall correlation 
between BRAF p.V600E and psammoma bodies in the samples analyzed was statistically significant 
(p = 0.012; chi-square test). 
All the BRAF non p.V600E mutations were identified between residues 593 and 607 (Figure 3). 
BRAF non p.V600E mutations were identified in two of four follicular adenomas that coexisted with 
the PTC (Table 2 and Figure 2). One follicular adenoma was BRAF p.K601E mutated, while the 
corresponding PTC was BRAF WT (Case 28 of Table S1, Table 3, and Figure 2). One oncocytic 
follicular adenoma carried two subclonal BRAF exon 15 mutations: p.V600K and p.S607P (Case 4 of 
Table S1, Table 3, and Figure 2), while the corresponding PTC was BRAF p.V600E mutated. 
Interestingly, BRAF p.S607P was also identified in a focus of follicular cell hyperplasia with oncocytic 
change adjacent to the oncocytic adenoma (Case 4 of Table S1 and Figure 1d). However, the majority 
of BRAF non p.V600E mutations were identified not in the adenomas—coexisting with the PTC as an 
incidental finding in the thyroidectomy specimen—but in the non neoplastic tissue adjacent to the 
PTC (Table 2, Table 3, and Figure 2). BRAF non p.V600E were present in 4 of 36 (11.1%) samples with 
follicular cell atypia, in 2 of 16 (12.5%) samples with follicular cell hyperplasia, and in 1 of 33 (3.0%) 
histologically normal samples. Importantly, if we exclude the cases of adenomas coexisting with the 
PTC, all BRAF non p.V600E mutations were identified only in tissue adjacent to PTCs harboring the 
BRAF p.V600E mutation. No BRAF exon 15 mutation was identified in thyroid samples surrounding 
PTCs that were BRAF wild type (with the exception of a BRAF p.K601E mutation present in a 
follicular adenoma coexisting with the PTC) (Case 28 of Table S1 and Table 4). We thus postulated 
that the restriction of BRAF non p.V600E mutations in thyroid tissue adjacent to PTCs p.V600E 
mutated may have biological significance. In order to understand whether the BRAF non p.V600E 
mutations we identified affect BRAF activity, we used PolyPhen-2 (Polymorphism Phenotyping v2) 
to assess the effect of the mutations in silico. All mutations were predicted as damaging, with the 
exception of BRAF p.S607P (Table 3). 
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Table 3. Type of BRAF exon 15 mutations found in thyroid tissue adjacent to PTC and their 
pathogenicity prediction score (PolyPhen-2). 
Thyroid Tissue Samples Adjacent the PTC (n = 
12) Mutation 
Reference 
(PMID) 
PolyPhen-2 
(Score) 
BRAF p.V600E    
PsB (n = 3) p.V600E PMID: 15035987 PD (0.971) 
BRAF non p.V600E    
ATY (n = 2), HYP (n = 1) p.G593D PMID: 19269016 PD (1.000) 
ATY (n = 1) p.A598T PMID: 22926515 PD (0.871) 
FA-ONC (n = 1) p.V600K PMID: 15035987 PD (1.000) 
ATY (n = 1) p.V600M PMID: 28783719 PD (0.904) 
FA (n = 1) p.K601E PMID: 15035987 PoD (0.784) 
HYP (n = 1) p.R603Q PMID: 23861977 PoD (0.786) 
NORM (n = 1) p.S607F PMID: 23861977 PD (0.998) 
FA-ONC (n = 1), HYP (n = 1) p.S607P PMID: 29176861 B (0.186) 
PsB: psammoma body; FA: follicular adenoma; FA-ONC: follicular adenoma, oncocytic; ATY: thyroid 
tissue with follicular cell atypia; HYP: thyroid tissue with follicular cell hyperplasia; and NORM: 
histologically normal thyroid tissue. Two distinct BRAF exon 15 mutations were identified in one 
oncocytic follicular adenoma (p.V600K and p.S607P; Case 4a) and in one focus of follicular cell 
hyperplasia (p.G593D and p.R603Q; Case 12b). PolyPhen-2 is an in silico tool that predicts mutation 
pathogenicity assigning the following scores: score 0–0.2, benign (B); score 0.2–0.85, possibly 
damaging (PoD); and score 0.85–1.00, probably damaging (PD). 
Table 4. BRAF exon 15 mutations in thyroid tissue adjacent to PTC. 
BRAF Exon 15 Mutations in Thyroid Tissue Adjacent to PTC with the BRAF p.V600E Mutation (n = 19) 
Total samples (n = 71) BRAF p.V600E BRAF non p.V600E BRAF WT NA 
Psammoma Body (n = 3) 3/71 (4.2%) - - - 
Follicular Adenoma (n = 1) - - 1/71 (1.4%) - 
Oncocytic Follicular Adenoma (n = 2) - 1/71 (1.4%) 1/71 (1.4%) - 
Atypical tissue (n = 30) - 4/71 (5.6%) 25/71 (35.2%) 1/71 (1.4%) 
Hyperplasia (n = 12) - 2/71 (2.8%) 10/71 (14.1%) - 
Normal tissue (n = 23) - 1/71 (1.4%) 21/71 (29.6%) 1/71 (1.4%) 
BRAF Exon 15 Mutations in Thyroid Tissue Adjacent to PTC BRAF Exon 15 Wild Type (n = 10) or with BRAF non 
p.V600E Mutation (n = 1) 
Total samples (n = 29) BRAF p.V600E 
BRAF non 
p.V600E BRAF WT NA 
Psammoma Body (n = 3) - - 3/29 (10.3%) - 
Follicular Adenoma (n = 3) - 1/29 (3.5%) 2/29 (6.9%) - 
Atypical tissue (n = 8) - - 7/29 (24.1%) 1/29 (3.5%) 
Hyperplasia (n = 4) - - 4/29 (13.8%) - 
Normal tissue (n = 11) - - 11/29 (37.9%) - 
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Figure 3. Schematic drawing of BRAF exon 15 mutations. The position and residue substitutions of 
all mutations identified are shown with respect to the standard BRAF nucleotide, codon, and amino 
acid residue sequence. 
2.4. Functional Characterization of MAPK Signaling by BRAF Non p.V600E Mutant Proteins 
To assess the functional activity of BRAF mutant proteins, ERK1/2 phosphorylation was 
evaluated in transiently transfected HEK-293 cells as an index of MAPK activation. In the MAPK 
signaling pathway, BRAF phosphorylates MEK1/2 at serine 217 and 221, and MEK1/2, in turn, 
phosphorylate ERK1/2 at threonine 202 and tyrosine 204 [4]. ERK1/2 phosphorylation in cells 
expressing BRAF non p.V600E mutated species found in the tissue adjacent to the PTC was compared 
to that of BRAF WT and BRAF p.V600E. ERK1/2 phosphorylation was higher in HEK-293 cells 
expressing BRAF p.V600E (5.6 fold, p < 0.0001) or BRAF p.K601E (3.9 fold, p < 0.005) when compared 
to cells expressing BRAF WT (Figure 4). In contrast, ERK1/2 phosphorylation by BRAF p.G593D, 
BRAF p.A598T, BRAF p.S607F, and BRAF p.S607P was similar to BRAF WT (Table S2, Figure 4, and 
Figure S1). Using the same HEK-293 in vitro model, we also analyzed BRAF phosphorylation in order 
to understand whether the BRAF non p.V600E mutations affect BRAF protein affinity for 
pyrophosphate. Interestingly, we observed that BRAF p.G593D, BRAF p.A598T, BRAF p.V600E, 
BRAF p.K601E, BRAF p.S607F, and BRAF p.S607P all showed BRAF phosphorylation levels similar 
to BRAF WT (Table S2, Figure 4, and Figure S1). 
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Figure 4. Functional characterization of BRAF p.G593D, BRAF p.A598T, BRAF p.S607F, and BRAF 
p.S607P compared to BRAF wild type (WT), BRAF p.V600E, BRAF p.K601E, and empty vector 
(EMPTY). (a) Effect of BRAF mutation on the MAPK signaling pathway: representative Western Blot 
of ERK, p-ERK, BRAF, and p-BRAF proteins in HEK-293 cells transiently transfected with wild type 
or mutant BRAF plasmids. Vinculin was used as a loading control. (b) Effect of BRAF mutation on 
ERK1/2 phosphorylation: densitometric analysis of Western Blots showing the p-ERK/ERK ratio in 
HEK-293 cells transiently transfected with wild type and mutant BRAF plasmids. HEK-293 cells 
transfected with BRAF-V600E and BRAF-K601E show increased activation of the MAPK pathway 
compared to BRAF WT, whereas HEK-293 cells transfected with BRAF-G593D, BRAF-A598T, BRAF-
S607F, and BRAF-S607P show similar MAPK activation to BRAF WT. Data have been normalized to 
nontransfected controls (not shown); data are reported as the mean ± SEM of at least two independent 
experiments. **: p < 0.005 and ***: p < 0.0001. (c) Effect of BRAF mutation on BRAF phosphorylation: 
densitometric analysis of Western Blots showing the p-BRAF/BRAF ratio in HEK-293 cells transiently 
transfected with wild type and mutant BRAF plasmids. There are no significant differences in BRAF 
phosphorylation levels between the different constructs. Data have been normalized to 
nontransfected control; data are reported as the mean ± SEM of at least two independent experiments. 
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3. Discussion 
In this study, we analyzed the mutational status of BRAF exon 15 in 100 samples from thyroid 
tissue surrounding 30 randomly selected PTCs to better understand the mutagenic process that leads 
to BRAF p.V600E mutated PTCs. 
The prevalence and type of BRAF exon 15 mutations in our PTCs are compatible with those 
reported in the literature; BRAF p.V600E was identified in 62.5% of classic PTC, in all tall cell PTC 
variants, and in the only infiltrative follicular variant PTC, all tumor types associated with a BRAF 
p.V600E-like mutational profile [2]. The only PTC with a BRAF non p.V600E exon 15 mutation carried 
BRAF p.V600A, an RAS-like BRAF exon 15 mutation compatible with the diagnosis of encapsulated 
follicular variant papillary carcinoma [2].   
Among the samples surrounding the PTCs, the only ones with BRAF p.V600E were those 
containing psammoma bodies—in the absence of identifiable tumor cells. In these samples, the 
presence of the mutation showed a perfect correspondence with that present in the PTC to which 
they were associated. The overall correlation between BRAF p.V600E and psammoma bodies in all 
the samples analyzed was statistically significant. Psammoma bodies have long been known to be a 
marker of PTC [8]. They are believed to develop from small groups or even single papillary carcinoma 
cells that, by undergoing necrosis, form a nidus for the deposition of successive layers of lamellated 
calcium salt deposits and are considered “the ghosts of dead papillae” [6,9]. The identification of 
BRAF p.V600E only in psammoma body samples surrounding BRAF p.V600E mutated papillary 
carcinoma is coherent with the hypothesis that the psammoma bodies in PTC originate indeed from 
dead papillary carcinoma cells. 
The mutations found in the adenomas that coexisted with the PTCs in the same thyroid gland 
were RAS-like BRAF mutations [4], typical of follicular-patterned lesions, and—not surprisingly—
were different from those of the PTCs to which they were associated. Specifically, the BRAF p.K601E 
mutation has been reported in follicular adenoma [10], while BRAF p.V600K has been reported in 
encapsulated follicular variant PTC [11]. Both mutations confer a gain of function to the BRAF 
protein, resulting in increased kinase activity [12]. 
Most BRAF non p.V600E exon 15 mutations were identified in the non neoplastic tissue adjacent 
to the PTC, and remarkably—after exclusion of the adenomas—all BRAF non p.V600E mutations 
were identified only in tissue adjacent to PTCs harboring the BRAF p.V600E mutation. They were 
present in approximately 10% of samples with follicular cell atypia histologically similar to that 
observed in multifocal fibrosing (sclerosing) thyroiditis [7] and in a similar proportion of samples 
with follicular cell hyperplasia. In a single case, a BRAF non p.V600E exon 15 mutation (p.S607F) was 
identified in histologically normal thyroid tissue.  
All BRAF non p.V600E exon 15 mutations identified belong to the enzymatic kinase domain of 
BRAF (Conserved Region 3, CR3) in the C-lobe (residues 535–717) that binds substrate proteins, with 
most mutations clustering in and around the DFG motif (D594, F595, and G596) and the activation 
loop (Residues 596–600) [13]. All of those found in non neoplastic samples have been previously 
reported in the literature and described in different types of tissues, including the thyroid gland. 
BRAF p.G593D has been identified in solid cell nest hyperplasia in association with BRAF p.V600E 
mutated PTC [14], while the BRAF p.R603Q and p.S607F mutations were reported in nevi, in 
association with BRAF p.V600E mutated melanomas [15], similar to what we observed in our cases. 
BRAF p.S607P and p.V600M have been reported in melanoma [12,16], while BRAF p.A598T has been 
identified in non small cell lung cancer [17]. 
MAPK signaling of BRAF p.G593D, BRAF p.A598T, BRAF p.S607F, and BRAF p.S607P found in 
non neoplastic samples was assessed in vitro. Kinase activity was compared to that of BRAF WT and 
to mutations well-known to lead to constitutive activation of the BRAF protein: BRAF p.V600E—with 
the highest kinase activity—and BRAF p.K601E [12]. Although our BRAF-mutated species were 
predicted to affect protein function in silico, all of them had kinase activity comparable to that of the 
BRAF WT protein, nor were they associated with increased phosphorylation levels of the mutated 
BRAF protein. It is tempting to speculate that, although our BRAF non p.V600E exon 15 mutations 
do not lead to increased MAPK pathway activation, they may induce the production of 
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protumorigenic cytokines and chemokines in cells carrying the mutation. Indeed, a connection 
between cancer development and chemokines has been proposed in several tumors—including those 
of the thyroid gland [18–26]. Some cytokines like CXCL8 (also known as interleukin-8 or neutrophil 
attractant/activation protein-1) are emerging as important players in the modulation of the thyroid 
cancer microenvironment, with a role for the initiation and maintenance of tumorigenesis [21].  
Taken together, our data indicate that a mutagenic process affecting BRAF exon 15 takes place 
in a subset of thyroid glands that develop BRAF p.V600E mutated PTCs. While the carcinoma 
develops only if the p.V600E mutation occurs, its development is accompanied by other exon 15 
mutations. Our data suggest that p.V600E is one of a cluster of BRAF mutations occurring in the 
thyroid tissue of some patients. Only mutations with definite oncogenic potential like BRAF p.V600E 
lead to the development of PTC; others without oncogenic potential are present in adjacent non 
malignant tissues, where they produce minor histologic abnormalities such as follicular cell atypia or 
hyperplasia. The cause of this putative mutagenic process is unlikely related to modification of the 
inactivation of the DNA mismatch repair system that is altered only in a minority of poorly and 
undifferentiated thyroid carcinomas [2,18]. It may, however, be linked to exposure of the thyroid 
parenchyma to chemical carcinogens, as in the case of simple nucleotide changes in other genes—
such as H-, K-, N-RAS—that are relevant for thyroid tumorigenesis [2,27]. The nature of this 
mutagenic process and its relevance for PTC development deserves further investigation. 
4. Materials and Methods 
4.1. Case Selection 
Thirty PTCs were randomly selected from the archives of the Anatomic Pathology Units of the 
Bellaria and Maggiore Hospital in Bologna (Italy). Tumor samples and surrounding thyroid tissues 
were obtained from formalin-fixed and paraffin-embedded (FFPE) tissue blocks processed following 
routine diagnostic procedures. PTCs (including tumors measuring 1 centimeter or less, also known 
as papillary microcarcinomas) were subtyped according to current classification schemes [5]. The 
study was approved by the Iinternal Review Board of the University of Bologna Medical Center 
(number: 51/2017/O/OssN). Information regarding the human material was managed using 
anonymous codes, and all samples were handled in compliance with the Helsinki Declaration. 
Follow-up information was not used in this study.  
4.2. Detection of BRAF Mutations by Next Generation Sequencing 
After routine hematoxylin and eosin (H&E) sections were cut for case review, two to four 
additional 10 μm thick sections were cut from each selected block, followed by one H&E control slide. 
To assure a strict histologic control for all samples analyzed, the area of interest was marked on this 
H&E control slide. The material for sequence analysis was then manually dissected under 
microscopic guidance from corresponding 10 μm sections using a sterile blade. All psammoma body 
samples used for molecular analysis were devoid of viable tumor cells. 
DNA for mutation analysis was extracted using the HighPure PCR Template Preparation Kit 
(Roche-Diagnostic, Manheim, Germany) following protocols specified by the manufacturer. DNA 
concentration was measured using the Quant-iT™ dsDNA BR Assay Kit on the Qubit™ Quantitation 
Platform (ThermoFisher Scientific, Waltham, MA, USA). BRAF exon 15 was analyzed by next-
generation sequencing (NGS) using the 454 GS-Junior (Roche Diagnostic) platform following the 
manufacturer’s instructions and according to previously reported protocols [28]. Briefly, at least 10 
ng of DNA was amplified targeting BRAF exon 15 using the following primers: sense 5′-
TGCTTGCTCTGATAGGAAAATGA-3′ and antisense 5′-TGGATCCAGACAACTGTTCAAA-3′ 
(Table 5). Primers were modified with universal tail sequences and multiple identifier (MID) 
nucleotides. After purification and quantification, emulsion-PCR and sequencing were performed 
according to the manufacturer’s protocol. Results were analyzed using Amplicon Variant Analyzer 
(AVA) software (Version 3.0, Roche Diagnostic, Mannheim, Germany). Only nucleotide variations 
observed in both strands with at least 5% of allele-read were considered for mutational calling. The 
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presence of all BRAF non p.V600E mutations was confirmed by repeating twice the analysis with the 
Next Generation Sequencing platform. 
Table 5. Primers used for sequencing and mutagenesis. 
BRAF (Exon 15) Primers for Next Generation Sequencing 
BRAF (Exon 15) 
FW: TGCTTGCTCTGATAGGAAAATGA 
RV: TGGATCCAGACAACTGTTCAAA 
BRAF (Exon 15) Primers for Mutagenesis 
p.G593D FW: GTAAAAATAGATGATTTTGGTCTAGC RV: TGTGAGGTCTTCATGAAG 
p.A598T 
FW: TTTTGGTCTAACTACAGTGAAATC 
RV: TCACCTATTTTTACTGTGAG 
p.V600E 
FW: CTAGCTACAGAGAAATCTCGATG 
RV: ACCAAAATCACCTATTTTTAC 
p.K601E FW: AGCTACAGTGGAATCTCGATG RV: AGACCAAAATCACCTATTTTTAC 
p.S607F 
FW: TGGAGTGGGTTCCATCAGTTT 
RV: TCGAGATTTCACTGTAGCTAG 
p.S607P FW: ATGGAGTGGGCCCCATCAGTT 
RV: CGAGATTTCACTGTAGCTAG 
BRAF (Exon 15) Primers for Sanger Sequencing 
BRAF (Exon 15) 
FW: ACACGCCAAGTCAATCATCC 
RV: TCTGACTGAAAGCTGTATGGATT 
In bold: nucleotide changes for mutagenesis. 
4.3. Mutant BRAF Plasmids Generation via Site-Directed Mutagenesis 
The pCMV6 construct encoding wild type BRAF (#40775) in frame with the FLAG tag was 
purchased from Addgene (Cambridge, MA, USA). Mutations—p.G593D, p.A598T, p.V600E, 
p.K601E, p.S607F, and p.S607P—were inserted using the Q5 Site direct Mutagenesis kit (New 
England Biolabs, Ipswich, MA, USA) according to manufacturer’s instructions. The oligonucleotides 
used for mutagenesis are reported in Table 5. Site-directed mutagenesis was verified by Sanger 
sequencing of plasmids using BRAF exon 15 targeting primers (see Table 5). 
4.4. Cell Lines and Transfection 
Cell models used were HEK-293 cells, and HEK-293 cells overexpressing wild type or mutant 
BRAF (p.G593D, p.A598T, p.V600E, p.K601E, p.S607F, and p.S607P). Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Euroclone, Milan, Italy) supplemented with 10% (v/v) 
fetal bovine serum, 2 mM L-glutamine, 100 U/ mL penicillin, and 100 μg/mL streptomycin (Sigma-
Aldrich, St. Louis, MO, USA) and grown in a humidified incubator at 37°C with 5% CO2 in the air. 
For transfection, 3.5 × 105 cells HEK-293 were seeded in complete medium. Twenty-four hours 
later, 4 μg of BRAF mutant plasmids were transfected using liposomes according to manufacturer’s 
instructions (Lipofectamine 3000, Thermo Fisher Scientific, Grand Island, NY, USA).  
4.5. Western Blots 
Forty-eight hours after transfection, HEK-293 cells were lysed in ice cold RIPA buffer: 50 mM 
HEPES (EuroClone), 1 mM EDTA (Sigma-Aldrich), 10% glycerol (Thermo Fisher Scientific, Waltham, 
MA, USA), 1% Triton X-100 (Sigma-Aldrich), and 150 mM NaCl in the presence of proteases and 
phosphatases inhibitors (Sigma-Aldrich). Total protein was measured using the Lowry assay (Bio-
Rad DC Protein Assay; Bio-Rad, Hercules, CA, USA) according to manufacturer’s instructions. 
Protein samples (15 μg) were subsequently loaded onto 4%–20% precast gels (Thermo Fisher 
Scientific). Gels were electrotransferred onto nitrocellulose membranes (Trans-Blot Turbo Transfer 
Cancers 2020, 12, 430 13 of 15 
 
System, Bio-Rad). Membranes were blocked in Tris Buffered Saline (TBS) with 1% Casein-TBS (Bio-
Rad) for 1 hour at room temperature and incubated overnight with phospho-ERK (Thr202/Tyr204) 
(rabbit, 1:1000), phospho-BRAF (Ser445) (rabbit, 1:250), vinculin (mouse, 1:10,000), γ-tubulin (mouse, 
1:10,000) (all purchased from Cell Signalling, Leiden, Netherlands), and FLAG tag (mouse, 1:10,000, 
Sigma-Aldrich) primary antibodies at 4°C. Membranes were washed three times in TBS containing 
0.1% Tween and incubated with peroxidase-conjugated secondary antibodies for 45 minutes at room 
temperature. Bands were visualized using WESTAR Supernova (Cyanagen, Bologna, Italy) and 
detected with the ChemiDoc™ XRS+ (Bio-rad). After the stripping using RENEW (Cyanagen, 
Bologna, Italy) buffer, membranes were incubated with total ERK (mouse, 1:1000) and total BRAF 
(rabbit, 1:250) (Cell Signalling, Leiden, Netherlands) primary antibodies overnight at 4°C. 
Membranes were washed three times in TBS containing 0.1% Tween and incubated with peroxidase-
conjugated secondary antibodies for 45 minutes at room temperature. Bands were visualized using 
WESTAR Supernova (Cyanagen, Bologna, Italy) and detected with the ChemiDoc™ XRS+ (Bio-rad). 
Phosphorylation levels of ERK1/2 and BRAF were evaluated by densitometric analysis of Western 
Blots performed with ImageLab software (Bio-Rad), and phosphorylated protein was normalized to 
respective total protein. All data were then normalized to nontransfected controls and reported as 
the mean ± SEM of at least two independent experiments. 
4.6. Statistical Analysis 
Statistical analysis was carried out using Prism 7 (GraphPad, San Diego, CA, USA). Western Blot 
experiments were carried out at least in duplicate. Results are expressed as the mean ± SEM. ANOVA 
test with Tukey’s multiple comparison test was used to analyze differences between groups. A p-
value < 0.05 (two-tailed) was considered to be statistically significant. 
5. Conclusions 
The analysis of thyroid tissue surrounding PTCs shows how a mutagenic process affecting BRAF 
exon 15 likely takes place in a subset of tumors, leading to the development of p.V600E mutated PTC 
and to minor histologic alterations of the thyroid parenchyma in the case of non oncogenic BRAF non 
p.V600E mutations. Our analysis also provides for the first time formal molecular proof that 
psammoma bodies originate from PTC and represent indeed “the ghosts of dead papillae”. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1. Figure S1: Western Blot 
analysis of ERK and BRAF, Table S1: Next generation sequencing results of individual samples, Table S2: 
Western Blot densitometry reading ratios of ERK and BRAF.  
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